Angeles Wealth Management LLC Makes New $82,000 Investment in Cue Biopharma, Inc. $CUE

Angeles Wealth Management LLC acquired a new position in Cue Biopharma, Inc. (NASDAQ:CUE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 120,000 shares of the company’s stock, valued at approximately $82,000. Angeles Wealth Management LLC owned about 0.16% of Cue Biopharma at the end of the most recent quarter.

Separately, GC Wealth Management RIA LLC purchased a new position in Cue Biopharma in the second quarter worth $2,273,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research report on Tuesday, October 14th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Cue Biopharma Stock Up 0.8%

Shares of NASDAQ CUE opened at $0.80 on Friday. Cue Biopharma, Inc. has a one year low of $0.54 and a one year high of $1.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.60 and a quick ratio of 1.60. The business’s fifty day moving average price is $0.77 and its 200-day moving average price is $0.75. The stock has a market capitalization of $61.19 million, a PE ratio of -1.42 and a beta of 1.55.

Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. Cue Biopharma had a negative return on equity of 230.13% and a negative net margin of 469.35%.The firm had revenue of $2.95 million for the quarter, compared to analysts’ expectations of $2.00 million. On average, equities research analysts anticipate that Cue Biopharma, Inc. will post -0.76 EPS for the current year.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.